Fosfomycin sodium, as a broad-spectrum antibiotic, operates by inhibiting the early synthesis of the bacterial cell wall. This mechanism differs from the targets of other mainstream antimicrobial drugs such as β-lactams, aminoglycosides, and quinolones. This uniqueness endows it with significant advantages in terms of its antibacterial spectrum, resistance profile, and safety profile. The following information relates to its comparison with similar drugs in the same class/clinical setting...

What is AKG? The “core component” of the cellular energy factory AKG (Alpha-Ketoglutarate) is a key intermediate metabolite in the tricarboxylic acid cycle (TCA cycle, also known as the Krebs cycle). Simply put, it is an essential “hub molecule” in the process by which cells convert food into energy. If…

Rulibactam, a product of Jingjing Pharmaceutical, has the following advantages compared to traditional β-lactamase inhibitors: it has a stable structure, does not induce drug resistance, and has a broad spectrum of enzyme inhibition. Rulibactam is a novel β-lactamase inhibitor with a DBO (Dibenzoyl-Oxazoline) structure. Its key characteristic is the absence of a β-lactam ring structure, which means it must be used in combination with imipenem or cilastatin to exert its antibacterial effect. This drug is primarily used for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.

精晶药业-危险废物管理制度 附件精晶药业-危险废物管理制度.pdf

精晶药业-危废培训管理办法 附件精晶药业-危废培训管理办法.pdf

精晶药业股份有限公司邢台食品添加剂分公司2026危险废物管理计划 附件精晶药业股份有限公司邢台食品添加剂分公司2026危险废物管理计划.pdf

精晶药业股份有限公司2026危险废物管理计划 精晶药业股份有限公司2026危险废物管理计划.pdf

Fosfomycin sodium is a broad-spectrum antibiotic with a very unique and efficient mechanism of action. The mechanism of action of fosfomycin sodium can be summarized as follows: it rapidly exerts its bactericidal effect at an early stage by irreversibly inhibiting the first step of bacterial cell wall synthesis. The specific process is as follows: 1. Target of action: The target of fosfomycin’s action is……

“Rulibactam” is a novel β-lactamase inhibitor with a non-β-lactam, diazabicyclooctane (DBO) structure. It is primarily used in combination with imipenem/cilastatin to treat infections caused by multi-drug resistant Gram-negative bacteria. The core function of Rulibactam produced by Jingjing Pharmaceutical is to “protect” the effectiveness of antibiotics…

Recently, the company held a core work meeting to comprehensively review the effectiveness of its work for the year 2025, assess the current business situation, determine the business objectives and key tasks for 2026, and build consensus. The company’s management, heads of various departments, and key core personnel attended the meeting. The meeting highlighted that in 2025, despite the complex and changing market environment, the company…